Estrella Immunopharma (NASDAQ:ESLA) Trading Up 26.5% - Here's Why

Key Points

• Shares jumped 26.5% intraday (trading as high as $1.95) on a massive volume surge of about 1.23 million shares, roughly a 2,097% increase versus average daily volume.
• Analyst views are mixed: D. Boral Capital has a Buy with an $8 target while Weiss Ratings reaffirmed a Sell, leaving a MarketBeat consensus of Hold with an average target price of $8.00.
• Estrella is a preclinical T‑cell therapy developer (market cap ≈ $73.4M) with a negative P/E and very low institutional ownership (~0.35%), though several funds modestly increased positions in the latest quarter.

Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) were up 26.5% on Tuesday . The company traded as high as $1.95 and last traded at $1.72. Approximately 1,226,373 shares changed hands during trading, an increase of 2,097% from the average daily volume of 55,822 shares. The stock had previously closed at $1.36.

Analyst Ratings Changes

Several research firms recently issued reports on ESLA. Weiss Ratings restated a "sell (d-)" rating on shares of Estrella Immunopharma in a research note on Wednesday, January 28th. Wall Street Zen upgraded Estrella Immunopharma from a "sell" rating to a "hold" rating in a research report on Saturday, January 31st. Finally, D. Boral Capital restated a "buy" rating and set a $8.00 price objective on shares of Estrella Immunopharma in a research report on Monday, February 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $8.00.

Estrella Immunopharma Stock Up 26.5%

The firm has a 50 day moving average price of $1.17 and a two-hundred day moving average price of $1.50. The company has a market cap of $73.38 million, a price-to-earnings ratio of -4.91 and a beta of 0.58.

Institutional Investors Weigh In On Estrella Immunopharma

Several large investors have recently added to or reduced their stakes in ESLA. Quadrature Capital Ltd acquired a new stake in Estrella Immunopharma during the fourth quarter worth approximately $43,000. State Street Corp boosted its position in shares of Estrella Immunopharma by 93.5% during the fourth quarter. State Street Corp now owns 43,252 shares of the company's stock valued at $67,000 after buying an additional 20,900 shares during the last quarter. XTX Topco Ltd boosted its position in shares of Estrella Immunopharma by 376.9% during the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company's stock valued at $77,000 after buying an additional 39,099 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Estrella Immunopharma during the fourth quarter valued at approximately $88,000. Finally, Geode Capital Management LLC lifted its holdings in Estrella Immunopharma by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company's stock worth $171,000 after acquiring an additional 8,318 shares during the period. Institutional investors and hedge funds own 0.35% of the company's stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.